The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID‐19

Chia Siang Kow, Syed Shahzad Hasan

Research output: Contribution to journalLetter

Abstract

Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.
Original languageEnglish
JournalObesity
DOIs
Publication statusE-pub ahead of print - 21 Jul 2020

Fingerprint Dive into the research topics of 'The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID‐19'. Together they form a unique fingerprint.

  • Cite this